Exact Sciences Corp. (NASDAQ: EXAS) today announced it would be devoting significant patient education resources toward the ability to request Cologuard® online through a telehealth provider. During the COVID-19 pandemic, people are staying home to avoid spreading the virus. Telehealth offers a way to screen more people at home, even during a public health crisis.
“Cancer doesn’t stop for anything. As the country faces a pandemic, we are letting people know they can request Cologuard online from a health care provider, without an office visit,” said Kevin Conroy, Exact Sciences chairman and CEO. “While Americans are at home trying to prevent the spread of COVID-19 in their communities, they can address another pressing public health issue and get screened for colorectal cancer.”
Colorectal cancer, the second leading cancer killer in the U.S.,1 is more treatable when detected early, making timely screening essential. 2 Despite this, an estimated 53,000 Americans will die this year from colorectal cancer.1 As the only FDA-approved stool DNA test for colorectal cancer, Cologuard found 92% of all colorectal cancers,3 including 94% in stages I and II4 in a large clinical study of patients 50 and older. The United States Preventive Services Task Force (USPSTF) recommends Cologuard as a screening test for average risk patients.5 Patients can use Cologuard without any preparation or changes in diet and medication. The Cologuard collection kit is delivered to a patient’s door, and home pick-up can be scheduled by calling Exact Sciences Laboratories’ 24/7 Customer Care Center at 1-844-870-8870. Test results are provided to the ordering physician in approximately 14 days.